GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Common Stock

GENinCode (LSE:GENI) Common Stock : £1.77 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Common Stock?

GENinCode's quarterly common stock stayed the same from Jun. 2023 (£0.96 Mil) to Dec. 2023 (£0.96 Mil) but then increased from Dec. 2023 (£0.96 Mil) to Jun. 2024 (£1.77 Mil).

GENinCode's annual common stock stayed the same from Dec. 2021 (£0.96 Mil) to Dec. 2022 (£0.96 Mil) and stayed the same from Dec. 2022 (£0.96 Mil) to Dec. 2023 (£0.96 Mil).

GENinCode Common Stock Historical Data

The historical data trend for GENinCode's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Common Stock Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
0.07 0.11 0.96 0.96 0.96

GENinCode Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 0.96 0.96 0.96 1.77

GENinCode Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

GENinCode Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Common Stock
Comparable Companies
LSE:GDR LSE:VRCI LSE:PRM LSE:ABDX LSE:LLAI LSE:AGL TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX XPAR:BIM ICLR
Traded in Other Exchanges
N/A
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
Website
https://www.genincode.com
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.